

1 **An examination of resting-state functional connectivity in patients with**
2 **active Crohn's disease**

3 Gita Thapaliya^{1*}, Sally Eldeghaidy^{2,3,4}, Shellie J Radford⁴, Susan T. Francis^{3,4}, Gordon William
4 Moran^{3,4,5*}

5 ¹Johns Hopkins University School of Medicine, Division of Child & Adolescent Psychiatry,
6 Department of Psychiatry and Behavioral Sciences, Baltimore, Maryland 21287, USA

7 ²The University of Nottingham, Division of Food, Nutrition & Dietetics, School of
8 Biosciences, Loughborough, United Kingdom

9 ³The University of Nottingham, Sir Peter Mansfield Imaging Centre, School of Physics and
10 Astronomy, Nottingham, United Kingdom.

11 ⁴The University of Nottingham, NIHR Nottingham Biomedical Research Centre, Nottingham
12 University Hospitals NHS Trust and School of Medicine, Nottingham, United Kingdom.

13 ⁵Translational Medical Sciences Unit, University of Nottingham

14

15 *** Correspondence:**

16 Corresponding Authors

17 gordon.moran@nottingham.ac.uk, gita.thapaliya@paediatrics.ox.ac.uk

18 **Keywords: Crohn's disease, gut-brain axis, gut inflammation, systemic inflammation**

19

20 **Abstract**

21 **Background:** Alterations in resting state functional connectivity (rs-FC) in Crohn's Disease (CD) have
22 been documented in default mode network (DMN) and frontal parietal network (FPN) areas, visual,
23 cerebellar, salience and attention resting-state-networks (RSNs), constituting a CD specific neural
24 phenotype. To date, most studies are in patients in remission, with limited studies in active disease.
25 **Methods:** 25 active CD cases and 25 age-, BMI- and gender-matched healthy controls (HC) were
26 recruited to a resting-state-functional Magnetic Resonance Imaging (rs-fMRI) study. Active disease
27 was defined as C-reactive protein>5mg/dl, faecal calprotectin>250µg/g, or through ileocolonoscopy or
28 MRE. rs-fMRI data were analysed using independent component analysis (ICA) and dual regression.
29 Differences in RSNs between HCs and active CD were assessed, and rs-FC was associated with disease
30 duration and abdominal pain. **Results:** Increased connectivity in the FPN (fusiform gyrus, thalamus,
31 caudate, posterior cingulate cortex, postcentral gyrus) and visual RSN (orbital frontal cortex) were
32 observed in CD versus HC. Decreased activity was observed in the salience network (cerebellum,
33 postcentral gyrus), DMN (parahippocampal gyrus, cerebellum), and cerebellar network (occipital
34 fusiform gyrus, cerebellum) in CD versus HCs. Greater abdominal pain scores were associated with
35 lower connectivity in the precuneus (visual network) and parietal operculum (salience network), and
36 higher connectivity in the cerebellum (frontal network). Greater disease duration was associated with
37 greater connectivity in the middle temporal gyrus and planum temporale (visual network). **Conclusion:**
38 Alterations in rs-FC in active CD in RSNs implicated in cognition, attention, emotion, and pain may
39 represent neural correlates of chronic systemic inflammation, abdominal pain, disease duration, and
40 severity.

41

42

43 **1. Introduction**

44 *1.1 Structural and functional brain alterations in Crohn's disease*

45 Crohn's disease (CD) is a chronic inflammatory bowel disease (IBD) characterized by a chronic
46 inflammatory response, with symptoms ranging from fatigue, abdominal pain, diarrhoea,
47 psychological comorbidities, and extraintestinal manifestations (EIMs) (Lamb *et al.*, 2019). Consistent
48 exposure to pain and inflammation in CD may impact the functional architecture of the brain. A
49 growing body of literature has demonstrated that CD and its comorbidities is associated with a distinct
50 intrinsic neural phenotype attributed to brain structural and functional alterations (Kong *et al.*, 2021;
51 Yeung, 2021). Systemic inflammation, chronic abdominal pain, dysregulated gut-brain signalling
52 pathways, and symptom-specific mechanisms may be involved in such brain structural and functional
53 alterations. Structural changes of the brain in active CD have previously been demonstrated by our
54 group in relation to symptoms such as fatigue, abdominal pain and EIMs (Thapaliya *et al.*, 2023), with
55 others demonstrating structural changes in remission (Yeung, 2021). To explore brain behaviour
56 associations in CD, task-based fMRI studies to stress (Agostini *et al.*, 2013, 2017) and pain (Rubio *et*
57 *al.*, 2016) have revealed differential brain responses in CD patients relative to healthy controls,
58 indicating an atypical response to unpleasant stimuli.

59 *1.2 The importance of studying functional connectivity patterns in Crohn's disease*

60 Resting state fMRI (rs-fMRI) measures spontaneous brain activity at rest. This does not depend on
61 how a patient performs to a task, meaning it is less burdensome to the patient. rs-fMRI helps to
62 understand how different brain regions communicate with each other to generate functional
63 connectivity patterns. A resting state network (RSN) constitutes a group of brain regions that are
64 spatially distant, but functionally connected and continuously communicating (Smitha *et al.*, 2017).
65 Comparisons of functional connectivity between CD patients during active disease and remission, and
66 with healthy controls, may aid the identification of neural biomarkers or signatures, and changes in
67 connectivity patterns to therapeutic interventions guiding personalized treatment approaches.

68 *1.3 Functional connectivity alterations reported in Crohn's Disease in remission*

69 Alterations in a number of RSNs, namely the default mode network (DMN), frontal-parietal network
70 (FPN) and executive control network (ECN), frontoparietal network (FPN), salience network (SN),
71 dorsal attention network (DAN), sensory-motor network (SMN), cerebellar network and visual
72 networks have been implicated in CD. The functions of these various RSNs are described in detail in
73 Table s1. A recent meta-analysis (Yeung, 2021) in CD reported reduced resting state functional
74 connectivity (rs-FC) in the cingulate gyrus, which is an integral part of the DMN. Consistent with this

75 meta-analysis, recent studies have reported reduced neural synchronization in key hubs of the DMN
76 (Kornelsen *et al.*, 2020; Thomann *et al.*, 2021; Zhang *et al.*, 2022) in association with greater abdominal
77 pain (Chen *et al.*, 2023). In contrast, another study reported increased rs-FC in the DMN in CD in
78 remission between the right precuneus and right posterior cingulate cortex (PCC) as compared with
79 HCs (Hou *et al.*, 2019). Apart from the DMN, increased rs-FC in the ECN has been reported between
80 the right middle frontal gyrus and the right inferior parietal lobe (Hou *et al.*, 2019). Further, increased
81 rs-FC between the FPN and salience network (SN) (Kornelsen *et al.*, 2020), and greater rs-FC in several
82 regions in the cerebellar, visual, and SN has been found in a mixed CD group compared with HCs.
83 Finally, reduced rs-FC in several regions of the right FPN and dorsal attention network (DAN) has also
84 been reported in CD in remission (Mallio *et al.*, 2020).

85 *1.4 Limited functional connectivity studies in active Crohn's disease*

86 Notably, the majority of the rs-FC studies conducted thus far have been conducted in CD participants
87 who are in remission, and until recently no published studies included participants in the active disease
88 phase (Huang *et al.*, 2022; Kong *et al.*, 2022; Li *et al.*, 2022; Prüß *et al.*, 2022; Agostini *et al.*, 2023;
89 Goodyear *et al.*, 2023). Of these studies in the active phase, one study restricted their analysis to the
90 anterior cingulate cortex ACC (part of the DMN) and showed rs-FC as well as structural and metabolic
91 changes in active CD (Kong *et al.*, 2022). Decreased rs-FC in the left calcarine of the primary visual
92 network (Li *et al.*, 2022) was found in active CD participants, with these changes associated with
93 greater CD duration. Greater rs-FC in the somatosensory cortex in the SN in active IBD patients with
94 chronic pain was found regardless of their inflammatory status relative to HCs (Prüß *et al.*, 2022). Most
95 recently, increased rs-FC has been reported within the left FPN (in the superior parietal lobe) in CD in
96 remission relative to active CD, as well as decreased rs-FC in the motor network (in parietal and motor
97 regions in active CD relative to HC (Agostini *et al.*, 2023). These mixed results highlight the need for
98 more studies in CD patients with active disease, as well as prospective studies to track connectivity
99 patterns in RSNs in active disease and remission and changes related to improvement in symptoms.

100 *1.5 Study aims and objectives*

101 We present results of an exploratory study with the primary aim being to study alterations in rs-FC in
102 active CD, to expand upon the currently limited literature.

103 Our primary objective is to compare rs-FC in active CD to HCs. Our secondary objective is to identify
104 neural correlates of abdominal pain, fatigue and disease duration in active CD participants.

105

106

107 **2. Methods**

108 *2.1 Basic protocol and patient recruitment*

109 This case-control study received research ethics committee approval from the National Research Ethics
110 Service [NRES] Committee East Midlands [REC reference 14/EM/0192 on 10/07/2015] and the
111 protocol was registered with clinicaltrials.gov [NCT02772458]. CD participants were identified
112 through a clinical database search and expression of interest list, and recruited from the IBD Clinic at
113 Nottingham University Hospitals. HCs were recruited from a participant database in the National
114 Institute of Health Research (NIHR) Nottingham Biomedical Research Centre, and local healthy
115 populations of Nottingham University Hospitals and the University of Nottingham recruited through
116 study fliers and social media. All CD participants and HCs read a participant information sheet and
117 gave their written informed consent before recruitment to the study.

118 CD participants' disease activity was defined through one or more objective markers of inflammation
119 defined as faecal calprotectin (FCP) of $>250 \mu\text{g/g}$ or C-reactive protein (CRP) $> 5 \text{ g/dL}$, or through
120 recent ileocolonoscopy (defined as presence of ulcerations), CT, magnetic resonance enterography
121 [MRE] showing active inflammatory disease (defined as presence of post-contrast enhancement or
122 visible mucosal ulcerations on cross-sectional imaging). This active disease characterization is
123 supported by the European Crohn's and Colitis organization – see review (Maaser *et al.*, 2019) CD
124 clinical symptoms were measured at inclusion using the Harvey-Bradshaw Index [HBI] score, a simple
125 index based on 5 items assessing symptoms and complications (including general well-being,
126 abdominal pain, number of liquid or soft stools per day, abdominal mass and EIM) (Harvey, 1980).
127 Exclusion criteria included malignant disease, BMI <18 or 35 kg/m^2 , significant cardiovascular or
128 respiratory disease, diabetes mellitus, current infection, neurological or cognitive impairment,
129 significant physical disability, significant hepatic disease or renal failure, abnormal blood results other
130 than those explained by CD including bleeding diatheses (in the case of HCs all unexplained blood
131 results were exclusion criteria), pregnancy or breastfeeding, recent corticosteroid exposure [in the past
132 3 months], severe CD where a delay in a change in medical treatment for 1-2 weeks would not be
133 clinically advisable, or contraindication to MRI (e.g. pacemaker). Stable doses of immunosuppressive
134 agents or biological agents were permitted details of these are provided in Table s2.

135 *2.2 Clinical assessments*

136 The IBD-Fatigue self-assessment scale (Section 1, which comprises 5 questions assessing frequency
137 and severity of fatigue which has been validated and shown to have excellent test-retest stability in

138 IBD) was used to identify IBD specific fatigue and its severity, frequency, and duration, where 0 = no
139 fatigue, 1 to 10 = moderate fatigue, 11 to 20 = severe fatigue (Czuber-Dochan *et al.*, 2014). Abdominal
140 pain was assessed using a 100 mm VAS (Mujagic *et al.*, 2015) with CD patients asked “Do you
141 currently suffer from abdominal (tummy) pain?” yes/no, if yes “How severe is your abdominal
142 (tummy) pain?” on a scale from 0 to 100. It should be noted that this is the level of subjective pain of
143 the CD patients experienced at the time of their MRI scan despite some being on medications. The
144 presence or absence of EIM was based on CD participants' responses to the “complications” section of
145 the HBI, where CD patients were asked to check boxes that apply (i) none (ii) arthralgia, (iii) uveitis,
146 (iv) erythema nodosum, (v) aphthous ulcers, (vi) pyoderma gangrenosum, (vii) anal fissure, (viii) new
147 fistula and (ix) abscess. Serum levels of interleukin-6 (IL-6), interleukin-1 beta (IL-1 β), and tumour
148 necrosis factor (TNF α) were measured using an immunoassay kit (Duoset ELISA Development, R&D
149 Systems, Inc, USA) as previously described (Negm *et al.*, 2019).

150 Depression and anxiety symptoms were measured using the Hospital Anxiety and Depression Scale
151 (HADS) (Zigmond and Snaith, 1983), a 14-item questionnaire graded on a 4-point Likert scale with
152 subscales of anxiety and depression, with a sum score ranging from 0 to 21 for each and a cut-off value
153 of >7 on either of the 2 subscales. Scores of 0–7 are considered normal, 8–10 are indicative of mild
154 anxiety/depression symptoms, 11–14 are indicative of moderate anxiety/depression symptoms, and
155 15–21 are indicative of severe anxiety/depression symptoms (Mikocka-Walus *et al.*, 2016).

156 2.3 Data acquisition

157 After an overnight fast, participants underwent a 10-minute resting-state BOLD fMRI scan on a 3T
158 Achieva scanner (Philips Medical Systems, Best, Netherlands). Images were collected with a 32-
159 channel receive head coil using a double-echo gradient-echo EPI (GE-EPI) acquisition scheme
160 (parameters: echo time (TE) of 20/49ms, 64 x 64 matrix, 3 mm isotropic voxels, 44 axial slices, TR =
161 2 s). Subjects were instructed to lay still inside the scanner with their eyes open. Physiological heart
162 rate and respiratory data were collected throughout. A 3D T₁-weighted MPRAGE image (1mm
163 isotropic resolution; TE/TR = 8.3/3.8 ms, flip angle = 8 °, SENSE factor =2, 160 slices, 256 x256
164 matrix) was also acquired.

165 2.3.1 Pre-processing

166 Specific nuisance signals were regressed out during the pre-processing steps. First, physiological noise
167 signal components associated with cardiac pulsation and respiration was removed using RETROICOR
168 (Glover et al, 2000). Pre-processing and analyses were then performed using the FMRIB Software
169 Library (FSL (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/>)). Head motion was corrected using multi-resolution

170 rigid body co-registration of volumes using MCFLIRT (Jenkinson *et al.*, 2002) and the six motion
171 parameters (3 translational and 3 rotational regressors) were regressed out from the data. In addition,
172 the mean time courses of cerebral white matter, ventricles, and whole brain were used as signal
173 regressors and masking of non-brain voxels was performed. Brain extraction was then performed on
174 the motion-corrected fMRI volumes and MPRAGE datasets using the Brain Extraction Tool software.
175 fMRI volumes were then registered to their subject-specific MPRAGE and moved to MNI152 standard
176 space by applying the transform of the co-registration of the MPRAGE volume to MNI152 standard
177 space. fMRI images were smoothed with a 6-mm spatial filter and a high-pass temporal filter cut-off
178 of 100s applied.

179 2.3.2 ICA analysis

180 The Multivariate Exploratory Linear Decomposition into Independent Components (MELODIC) tool
181 was used to perform single-session independent component analysis (ICA) on all subjects to produce
182 30 component maps. Any nuisance components arising from noise and motion-related artifacts were
183 removed following visual inspection (Griffanti *et al.*, 2017) and the *fslregfilt* function was used to
184 regress out nuisance components from each dataset. We chose to estimate 30 component maps, which
185 is a typical number used in the literature, as this has been shown to provide a good trade-off between
186 providing a good representative of the fMRI data structure whilst making the analysis and interpretation
187 more manageable (Wang and Li, 2015; Vergun *et al.*, 2016). Group ICA was then performed on the
188 noise-free datasets from the single session ICA step using multisession temporal concatenation to
189 produce 30 component maps representing the average RSNs of the entire study population comprising
190 CD participants and HCs, as well as a group ICA performed for the CD group only and the HC group
191 only.

192 2.3.3 Group ICA with dual regression

193 Dual regression was performed using the HC group 30 component maps as the network template. The
194 HC group network was chosen as this is more robust in the absence of disease-related alterations and
195 more sensitive in detecting group differences in the dual regression as compared with using the entire
196 (CD and HC group) study population component maps (Rytty *et al.*, 2013). Variance normalization
197 was used, reflecting the differences in both activity and spatial spread of RSNs.

198 Dual regression was carried out in three stages. In Stage 1, the subject-specific time course for
199 each network template was extracted using a multivariate spatial regression of the template maps
200 against each subject's fMRI data. In Stage 2, subject-specific time courses from Stage 1 were used in
201 a second multivariate temporal regression against the subjects' fMRI data to identify subject-specific

202 spatial maps corresponding to each network template of interest. In Stage 3, a two-sample unpaired t-
203 test between the CD and HC group was performed, where different component maps were collected
204 across subjects into single 4D files (i.e. per original ICA map) and tested voxel-wise by non-parametric
205 permutation using the FSL randomize tool (Winkler *et al.*, 2014) with 5000 permutations and TFCE to
206 control for multiple comparisons. Differences between groups were tested at $p < 0.05$ with voxel-wise
207 changes in the FSL randomize tool. It is important to highlight that using the spatial maps output by
208 dual-regression in such a test can result in areas of significant difference both "within" and not "within"
209 the group-average HC component map for that RSN. Areas not "within" the group-average HC
210 component map for that RSN can be interpreted to represent that the connectivity of this area of the
211 RSN is different between the two groups. For example, this can result if an area has a weak positive
212 synchrony, with the main areas of a RSN in the HC group and a weak negative synchrony in the CD
213 group.

214 For the CD group, at stage 2 a General linear model (GLM) was created to investigate the
215 correlation between the RSNs and clinical scores of disease duration, abdominal pain score, and IBD
216 fatigue score, as well as anxiety and depression, using permutation-based non-parametric testing (5000
217 permutations) and TFCE, with cluster significance threshold of $p < 0.05$. We then tested if these
218 survived multiple comparisons using Bonferroni method. The Juelich histological atlas incorporated in
219 FSL and the Harvard-Oxford cortical and subcortical atlases (Harvard Centre for Morphometric
220 Analysis) provided within the FSL4 software were used to identify anatomical characteristics of the
221 resulting maps.

222

223 *2.4. Analysis of clinical and behavioral data*

224 Analyses of non-imaging data were carried out using SPSS Statistics version 28.0. All variables were
225 tested for normality using the Shapiro-Wilk test. Normal data were expressed as mean \pm standard error
226 of the mean (SEM) and non-parametric data as median (interquartile range, IQR). Correlation between
227 different variables was evaluated using the Spearman for non-parametric data and Pearson's correlation
228 for parametric data.

229 **3. Results**

230 In total, 25 CD participants and 25 age, BMI, and gender-matched HCs were included in this study.
231 Figure 1 provides a consort diagram outlining the number of participants recruited for the study. Table
232 1 provides the demographic, behavioural, and clinical characteristics of the CD participants and HCs.
233 In 20/25 cases, disease activity was defined through ileocolonoscopy or MRE and in 4/5 cases it was
234 defined through CRP and faecal calprotectin together. Further information on each of the CD patient

235 characteristics including the measure(s) used to define active disease and any medications are provided
236 in Table S2. The CD and HC groups did not differ in any of their behavioural characteristics, except
237 for the HADS depression score, for which CD participants had significantly greater scores than HCs
238 ($P=0.004$). Figure s1 provides a heat map of the correlation between each of the clinical and
239 behavioural variables.

240 *3.1 Comparison of rs-FC between CD patients and HCs*

241 Figure 2 shows example RSNs generated for the template network of the HC group only. This network
242 was used in the dual regression analysis to assess differences in rs-FC between the CD participants and
243 HCs.

244 **Table 2** provides a summary of the regional alterations in rs-FC in RSNs between the CD participants
245 in active disease and HCs. CD participants in active disease showed increased rs-FC compared to HCs
246 in the inferior temporal gyrus and lateral occipital cortex in the dorsal and cranial Visual Network, and
247 in the OFC in the medial Visual Network. Also, greater rs-FC was observed in the FPN in the inferior
248 temporal gyrus, occipital fusiform gyrus, thalamus, caudate, PCC, postcentral gyrus and lingual gyrus
249 in CD participants compared to HCs. Reduced rs-FC in CD participants compared to HCs was shown
250 in the PHG and cerebellum of the DMN, the cerebellum, lingual gyrus and postcentral gyrus of the SN,
251 and the occipital fusiform gyrus and cerebellum in the Cerebellar Network.

252 *3.2. Correlation of pain scores, fatigue scores, disease duration in CD patients*

253 **Table 3** shows that in visual and salience RSNs, brain regions negatively correlated with abdominal
254 pain scores in active CD participants, whilst in the frontal network the cerebellum was shown to
255 positively correlate with abdominal pain scores.

256 **Table 4** shows that in the Visual Network brain regions correlated with disease duration in active CD
257 participants. There was no significant correlation between fatigue scores, or HADS anxiety and
258 depression scores and any of the RSNs.

259 **4. Discussion**

260 In this work we explore alterations in resting state connectivity in the active phase of CD, which has
261 received limited attention as prior studies generally focus on CD in remission. In this section,
262 alterations in the connectivity patterns seen in the visual network, FPN, DMN, salience and cerebellar
263 networks in active CD relative to HCs are first discussed with relation to CD symptoms and
264 manifestations. Correlations in rs-FC with clinical features of abdominal pain and disease duration are
265 then reviewed, followed by a discussion of study limitations and future research directions.

266

267 *4.1 Alterations in rs-FC in the visual network*

268 Greater rs-FC in the occipital region of the visual network was seen, a finding in line with Kornelsen
269 *et al.* (Kornelsen *et al.*, 2020) who compared a mixed CD group (active/remission, n=7/28) with HCs
270 We also show greater rs-FC in the OFC (an area implicated in executive function), inferior temporal
271 gyrus (visual perception) and lateral occipital (object recognition) in the visual network in active CD
272 participants relative to HCs. Alterations in rs-FC in the visual network may manifest as a result of
273 lower cognitive functioning in CD participants, with impaired information processing speed, task-
274 switching abilities and verbal function having been documented in CD (Golan *et al.*, 2016; Petruo *et*
275 *al.*, 2017; Nair *et al.*, 2019).

276 *4.2 Alterations in rs-FC in the frontal parietal network (FPN)*

277 A number of rs-FC alterations were evident in the FPN, with greater rs-FC in the FPN in the inferior
278 temporal gyrus (visual perception), occipital fusiform gyrus (object and facial expression recognition),
279 thalamus (relaying and integrating information), caudate (reward), PCC (pain processing), and
280 postcentral gyrus (somatosensory processing) and lingual gyrus (visual information processing) (Table
281 2). Such changes in the FPN are in agreement with previous studies (Thomann *et al.*, 2017; Kornelsen
282 *et al.*, 2020; Mallio *et al.*, 2020), two of these studies also used an ICA dual regression approach and
283 reported a reduction in rs-FC in the right FPN in multiple frontal, temporal and occipital regions in CD
284 in remission compared with HCs (Mallio *et al.*, 2020), as well as increased rs-FC within the left FPN
285 (in the superior parietal lobe) in CD patients in remission relative to active CD patients (Agostini *et al.*,
286 2023). Previous neuroimaging studies have shown that the FPN is critical for the regulation of
287 emotions. Our rs-FC findings in the FPN could be implicated in the inhibition of mentalization
288 processes recently highlighted in patients with IBD (Agostini *et al.*, 2019; Engel *et al.*, 2021). Chronic
289 exposure to physical discomfort in the context of CD has been suggested to lead to reduced
290 mentalization (the ability to understand one's own behavior and the behavior of others) and result in
291 alterations in brain areas that are involved in emotion processing. Altered rs-FC in multiple regions in
292 the FPN, may manifest as heightened sensitivity to visceral sensory information such as increased
293 symptom monitoring, hypervigilance, as well as anxiety around anticipation of abdominal pain,
294 cramps, and diarrhoea.

295 *4.3 Alterations in rs-FC in the cerebellar network*

296 In the cerebellar network, reduced rs-FC was seen in the occipital fusiform gyrus (object and facial
297 recognition) and cerebellum (motor and emotion) in CD participants compared with HCs. Alterations
298 in rs-FC within the cerebellar network have also been previously reported by Kornelsen *et*
299 *al.* (Kornelsen *et al.*, 2020) who show greater rs-FC in the cerebellar network in the left superior lateral

300 occipital in CD group (active/remission,n=7/28) compared with HCs. The cerebellar network is
301 associated with action and somesthesia (bodily perception and somatosensory processing) and the rs-
302 FC alteration in CD patients may also be linked with impaired emotional processing, and heightened
303 sensitivity to negative physical and visceral.

304 *4.4 Alterations in rs-FC in the DMN*

305 Our finding of alterations in rs-FC in the DMN has been widely reported in CD literature in remission
306 and active disease(Thomann *et al.*, 2017, 2021; Bao *et al.*, 2018; Liu *et al.*, 2018; Hou *et al.*, 2019;
307 Kornelsen *et al.*, 2020; Li *et al.*, 2022; Goodyear *et al.*, 2023). We show reduced rs-FC in the DMN in
308 the parahippocampal gyrus (visuospatial processing and episodic memory) and cerebellum in active
309 CD participants compared with HCs. This may represent disrupted self-referentially processing and
310 self-regulation, which may have implications pertaining to body perception and image as seen in
311 anorexia nervosa (Cowdrey *et al.*, 2014).

312 *4.5 Alterations in rsFC in salience network (SN)*

313 In the SN, we identified reduced rs-FC in the cerebellum (motor function and emotion), lingual gyrus
314 (visual information processing) and postcentral gyrus (somatosensory processing) in active CD
315 participants compared with HCs. Alterations in rs-FC in the SN have been documented before
316 (Kornelsen *et al.*, 2020; Prüß *et al.*, 2022), with one study showing greater rs-FC in the SN in the left
317 planum temporale in CD participants in remission compared with HC (Kornelsen *et al.*, 2020). Another
318 study using a ICA dual regression approach showed increased rs-FC in the secondary somatosensory
319 cortex in the SN in active IBD (78% CD, 22% UC) relative to HC(Prüß *et al.*, 2022). The SN has been
320 implicated in orientation toward salient emotional stimuli, conflict monitoring, response choice,
321 information integration, and pain-related processes during acute stimulus-induced pain(Heine *et al.*,
322 2012). We hypothesize that disrupted connectivity in SN may have implications pertaining to
323 emotional dysregulation and impaired processing of sensory stimuli explaining heightened pain
324 perception, anticipation(Huang *et al.*, 2016; Rubio *et al.*, 2016) and dysregulated psychological stress
325 responses(Agostini *et al.*, 2013).

326 *4.6. Association between rsFC and abdominal pain and disease duration*

327 On correlating with clinical scores, we show that greater abdominal pain was associated with reduced
328 rs-FC in the precuneus (body image and weight consciousness) and the parietal operculum (implicated
329 in pain) and in the medial visual RSN and SN (IC8) respectively. The SN has been implicated in chronic
330 abdominal pain in active CD(Prüß *et al.*, 2022). We further show that greater abdominal pain was
331 associated with greater rs-FC in the cerebellum in the frontal RSN (IC11) (Table 3). Altered rs-FC in
332 the SN, may be linked with heightened reactivity to pain and anticipation of discomfort in CD.

333 We show that greater disease duration was associated with greater rs-FC in the middle temporal gyrus
334 (language and semantic memory processing) and planum temporale (auditory perception and attention)
335 in the visual anterior RSN (IC2). Altered functional connectivity in regions in the visual network has
336 been reported before (Li *et al.*, 2022), where reduced rs-FC in the left calcarine was associated with
337 greater disease duration. We postulate that disease duration is one of the variables that to an extent
338 affect disease burden which may be related to the changes seen in visual network due to the increased
339 chronic exposure of the CNS to symptom and chronic inflammatory stimuli. We found no significant
340 association between fatigue, anxiety or depression scores and rs-FC in any of RSNs.

341 *4.7 Study Limitations*

342 There are some limitations of the study. As expected, CD patients were on a number of differing types
343 and dosage of immunosuppressive agents or biological agents as prescribed for their clinical care,
344 which may have influenced their rs-fMRI patterns. A limited number of studies have assessed the
345 effects of immunosuppressive medications on rs-fMRI, which have shown small or minimal effects
346 which are drug dependent. In one study, the effects of anti-TNF therapy and interferon- α treatment was
347 shown to result in small regional patterns of global brain connectivity changes, but the changes did not
348 correlate suggesting independent underlying processes (Martins *et al.*, 2022). In a study of the effects
349 of fingolimod therapy for multiple sclerosis (Bhattacharyya *et al.*, 2020) no changes in motor or FPN
350 rs-fMRI were observed over 24 months. Here, we could not study influence of medications on our rs-
351 fMRI measures, instead we use the CD participants subjective experience of abdominal pain, fatigue
352 at the time of the MRI scan as covariates of interest.

353 Our ICA approach using a study specific HC network template is a strength as it is a model-free, data
354 driven approach with few priori assumptions, however, it may be less sensitive to inter-individual
355 variation. This study is limited by its sample size and its cross-sectional nature which only provided a
356 small window to assess the association between mild abdominal pain and rs-FC. It is important to note
357 that, due to variations in the data analysis methods, patient population, disease status/activity/severity,
358 sample size/heterogeneity, concomitant medication, and disease-related symptoms, results need to be
359 interpreted with caution when contrasting findings with other published literature and so this warrants
360 further investigation in a large homogenous sample of active CD.

361 *4.8 Future Research Directions*

362 Future studies assessing rs-FC in CD, could use a non-gastrointestinal chronic inflammatory disease
363 patient group as a comparator to dissect the relationship between gastrointestinal, systemic
364 inflammation and rs-FC. In future, it would also be of interest to perform studies of rs-FC whilst
365 longitudinally tracking CD patients during the active phase of the disease and in remission, to see if

366 the change in connectivity in differing network patterns (visual, FPN, cerebellar, SN, DMN) are
367 associated with improved disease outcomes and cognitive function. This could then be related to
368 underlying changes in symptoms and manifestations. Identification of a neural phenotype through rs-
369 FC specific to active CD status, may help guide intervention constituting a neurobehavioral precision
370 medicine approach to treatment.

371

372 **5. Conclusion**

373 Alterations in rs-FC between the CD and HC groups in the RSNs implicated in cognition, attention,
374 emotion, and pain may represent neural correlates of chronic systemic inflammation, abdominal pain,
375 and disease duration constituting a unique neurobehavioral phenotype specific to active CD.

376 **Conflict of Interest**

377 Authors of this paper have no conflict of interests to declare

378 **Author Contributions**

379 GT wrote the original draft, acquired, curated and analyzed the data. SE acquired and curated data
380 and edited the manuscript. SJR recruited patients, acquired and curated data and edited manuscript.
381 STF and GWM conceptualized, supervised, edited the manuscript and acquired funding for this work

382 **Funding**

383 Crohn's & Colitis Foundation of America (336416), Medical Research Council (MRC), Doctoral
384 Training Programme (DTP)

385 **Acknowledgments**

386 We would like to thank our participants for taking the time to volunteer in our study and staff at the
387 Sir Peter Mansfield Imaging Centre.

388 **Data Availability Statement**

389 The datasets used and/or analysed during the current study are available from the corresponding
390 author on reasonable request.

391 **References**

392 Agostini, A. *et al.* (2013) 'Functional magnetic resonance imaging study reveals differences in the
393 habituation to psychological stress in patients with Crohn's disease versus healthy controls', *Journal*
394 *of Behavioral Medicine*, 36(5), pp. 477–487. doi: 10.1007/s10865-012-9441-1.

395 Agostini, A. *et al.* (2017) ‘Stress and brain functional changes in patients with Crohn’s disease: A
396 functional magnetic resonance imaging study’, *Neurogastroenterology and Motility*, pp. 1–10. doi:
397 10.1111/nmo.13108.

398 Agostini, A. *et al.* (2019) ‘Attachment and Mentalizing Abilities in Patients with Inflammatory
399 Bowel Disease.’, *Gastroenterology research and practice*. Egypt, 2019, p. 7847123. doi:
400 10.1155/2019/7847123.

401 Agostini, A. *et al.* (2023) ‘Differential Brain Structural and Functional Patterns in Crohn’s Disease
402 Patients are Associated with Different Disease Stages’, *Inflammatory Bowel Diseases*, (March), pp.
403 1–9. doi: 10.1093/ibd/izad029.

404 Bao, C. *et al.* (2018) ‘Difference in regional neural fluctuations and functional connectivity in
405 Crohn’s disease: a resting-state functional MRI study’, *Brain Imaging and Behavior*. Springer US,
406 0(0), pp. 1–9. doi: 10.1007/s11682-018-9850-z.

407 Bhattacharyya, P. K. *et al.* (2020) ‘Changes in structural and functional connectivity during two years
408 of fingolimod therapy for multiple sclerosis.’, *Magnetic resonance imaging*. Netherlands, 74, pp.
409 113–120. doi: 10.1016/j.mri.2020.09.015.

410 Chen, F. *et al.* (2023) ‘Disruption of Periaqueductal Gray-default Mode Network Functional
411 Connectivity in Patients with Crohn’s Disease with Abdominal Pain.’, *Neuroscience*. United States,
412 517, pp. 96–104. doi: 10.1016/j.neuroscience.2023.03.002.

413 Cowdrey, F. A. *et al.* (2014) ‘Increased resting state functional connectivity in the default mode
414 network in recovered anorexia nervosa.’, *Human brain mapping*, 35(2), pp. 483–491. doi:
415 10.1002/hbm.22202.

416 Czuber-Dochan, W. *et al.* (2014) ‘Development and psychometric testing of inflammatory bowel
417 disease fatigue (IBD-F) patient self-assessment scale’, *Journal of Crohn’s and Colitis*, 8(11), pp.
418 1398–1406. doi: 10.1016/j.crohns.2014.04.013.

419 Engel, F. *et al.* (2021) ‘Higher Levels of Psychological Burden and Alterations in Personality
420 Functioning in Crohn’s Disease and Ulcerative Colitis.’, *Frontiers in psychology*. Switzerland, 12, p.
421 671493. doi: 10.3389/fpsyg.2021.671493.

422 Glover, G. H., Li, T. Q. and Ress, D. (2000) ‘Image-based method for retrospective correction of
423 physiological motion effects in fMRI: RETROICOR’, *Magnetic Resonance in Medicine*, 44(1), pp.
424 162–167. doi: 10.1002/1522-2594(200007)44:1<162::AID-MRM23>3.0.CO;2-E.

425 Golan, D. *et al.* (2016) ‘Cognitive Function of Patients with Crohn’s Disease is Associated with
426 Intestinal Disease Activity’, *Inflammatory Bowel Diseases*, 22(2), pp. 364–371. doi:
427 10.1097/MIB.0000000000000594.

428 Goodyear, B. G. *et al.* (2023) ‘Multimodal Brain MRI of Deep Gray Matter Changes Associated
429 With Inflammatory Bowel Disease.’, *Inflammatory bowel diseases*. England, 29(3), pp. 405–416.
430 doi: 10.1093/ibd/izac089.

431 Griffanti, L. *et al.* (2017) ‘Hand classification of fMRI ICA noise components’, *NeuroImage*,
432 154(June 2016), pp. 188–205. doi: 10.1016/j.neuroimage.2016.12.036.

433 Harvey, B. (1980) ‘Index of Crohn’S Disease Activity’, *The Lancet*, 315(8170), p. 711. doi:
434 10.1016/S0140-6736(80)92858-5.

435 Heine, L. *et al.* (2012) ‘Resting state networks and consciousness Alterations of multiple resting state
436 network connectivity in physiological, pharmacological, and pathological consciousness states’,
437 *Frontiers in Psychology*, 3(AUG), pp. 1–12. doi: 10.3389/fpsyg.2012.00295.

438 Hou, J. *et al.* (2019) ‘Alterations in resting-state functional connectivity in patients with Crohn’s
439 disease in remission’, *Scientific Reports*, 9(1), pp. 1–9. doi: 10.1038/s41598-019-43878-0.

440 Huang, J. S. *et al.* (2016) ‘Pilot study of functional magnetic resonance imaging responses to somatic
441 pain stimuli in youth with functional and inflammatory gastrointestinal disease’, *Journal of Pediatric*
442 *Gastroenterology and Nutrition*, 63(5), pp. 500–507. doi: 10.1097/MPG.0000000000001390.

443 Huang, M. *et al.* (2022) ‘Alterations of Regional Homogeneity in Crohn’s Disease With
444 Psychological Disorders: A Resting-State fMRI Study.’, *Frontiers in neurology*, 13, p. 817556. doi:
445 10.3389/fneur.2022.817556.

446 Jenkinson, M. *et al.* (2002) ‘Improved optimization for the robust and accurate linear registration and
447 motion correction of brain images.’, *NeuroImage*, 17(2), pp. 825–41. doi: 10.1006/nimg.2002.1132.

448 Kong, N. *et al.* (2021) ‘Changes in the anterior cingulate cortex in Crohn’s disease: A neuroimaging
449 perspective.’, *Brain and behavior*, 11(3), p. e02003. doi: 10.1002/brb3.2003.

450 Kong, N. *et al.* (2022) ‘Neurophysiological Effects of the Anterior Cingulate Cortex on the
451 Exacerbation of Crohn’s Disease: A Combined fMRI-MRS Study.’, *Frontiers in neuroscience*, 16,
452 p. 840149. doi: 10.3389/fnins.2022.840149.

453 Kornelsen, J. *et al.* (2020) ‘Brain Resting-State Network Alterations Associated With Crohn’s
454 Disease’, *Frontiers in Neurology*, 11(February), pp. 1–9. doi: 10.3389/fneur.2020.00048.

455 Lamb, C. A. *et al.* (2019) ‘British Society of Gastroenterology consensus guidelines on the
456 management of inflammatory bowel disease in adults.’, *Gut*, 68(Suppl 3), pp. s1–s106. doi:
457 10.1136/gutjnl-2019-318484.

458 Li, L. *et al.* (2022) ‘Altered Intra- and Inter-Network Functional Connectivity in Patients With
459 Crohn’s Disease: An Independent Component Analysis-Based Resting-State Functional Magnetic
460 Resonance Imaging Study.’, *Frontiers in neuroscience*, 16, p. 855470. doi:
461 10.3389/fnins.2022.855470.

462 Liu, P. *et al.* (2018) ‘Altered topological patterns of brain functional networks in Crohn’s disease’,
463 *Brain Imaging and Behavior*. Springer US, 12(5), pp. 1466–1478. doi: 10.1007/s11682-017-9814-8.

464 Maaser, C. *et al.* (2019) ‘ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial
465 diagnosis, monitoring of known IBD, detection of complications’, *Journal of Crohn’s and Colitis*,
466 13(2), pp. 144-164K. doi: 10.1093/ecco-jcc/jjy113.

467 Mallio, C. A. *et al.* (2020) ‘Within-network brain connectivity in Crohn’s disease patients with
468 gadolinium deposition in the cerebellum’, *Neuroradiology*. *Neuroradiology*, 62(7), pp. 833–841. doi:
469 10.1007/s00234-020-02415-x.

470 Martins, D. *et al.* (2022) ‘Transcriptomic and cellular decoding of functional brain connectivity
471 changes reveal regional brain vulnerability to pro- and anti-inflammatory therapies.’, *Brain*,
472 *behavior, and immunity*. Netherlands, 102, pp. 312–323. doi: 10.1016/j.bbi.2022.03.004.

473 Mikocka-Walus, A. *et al.* (2016) ‘Symptoms of Depression and Anxiety Are Independently
474 Associated With Clinical Recurrence of Inflammatory Bowel Disease’, *Clinical Gastroenterology*
475 *and Hepatology*, 14(6), pp. 829-835.e1. doi: 10.1016/j.cgh.2015.12.045.

476 Mujagic, Z. *et al.* (2015) ‘Systematic review: Instruments to assess abdominal pain in irritable bowel
477 syndrome’, *Alimentary Pharmacology and Therapeutics*, 42(9), pp. 1064–1081. doi:
478 10.1111/apt.13378.

479 Nair, V. A. *et al.* (2019) ‘A Verbal Fluency Task-Based Brain Activation fMRI Study in Patients
480 with Crohn’s Disease in Remission’, *Journal of Neuroimaging*, pp. 1–10. doi: 10.1111/jon.12634.

481 Negm, O. H. *et al.* (2019) ‘Patients with tumour necrosis factor (TNF) receptor-associated periodic
482 syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulation’, *Clinical and Experimental*
483 *Immunology*, 197(3), pp. 352–360. doi: 10.1111/cei.13306.

484 Petruo, V. A. *et al.* (2017) ‘Specific neurophysiological mechanisms underlie cognitive inflexibility

485 in inflammatory bowel disease’, *Scientific Reports*, 7(1), pp. 1–9. doi: 10.1038/s41598-017-14345-5.

486 Prüß, M. S. *et al.* (2022) ‘Functional Brain Changes Due to Chronic Abdominal Pain in
487 Inflammatory Bowel Disease: A Case-Control Magnetic Resonance Imaging Study.’, *Clinical and*
488 *translational gastroenterology*. United States. doi: 10.14309/ctg.0000000000000453.

489 Rubio, A. *et al.* (2016) ‘Brain responses to uncertainty about upcoming rectal discomfort in quiescent
490 Crohn’s disease - a fMRI study’, *Neurogastroenterology & Motility*. doi: 10.1111/nmo.12844.

491 Rytty, R. *et al.* (2013) ‘GroupICA dual regression analysis of resting state networks in a behavioral
492 variant of frontotemporal dementia’, *Frontiers in Human Neuroscience*, 7(August), pp. 1–10. doi:
493 10.3389/fnhum.2013.00461.

494 Smitha, K. A. *et al.* (2017) ‘Resting state fMRI: A review on methods in resting state connectivity
495 analysis and resting state networks’, *Neuroradiology Journal*, 30(4), pp. 305–317. doi:
496 10.1177/1971400917697342.

497 Thapaliya, G. *et al.* (2023) ‘The relationship between Central Nervous System morphometry changes
498 and key symptoms in Crohn’s disease.’, *Brain imaging and behavior*. United States, 17(2), pp. 149–
499 160. doi: 10.1007/s11682-022-00742-6.

500 Thomann, A. K. *et al.* (2017) ‘Intrinsic neural network dysfunction in quiescent Crohn’s Disease’,
501 *Scientific Reports*. Springer US, 7(1), pp. 1–10. doi: 10.1038/s41598-017-11792-y.

502 Thomann, A. K. *et al.* (2021) ‘Exploring joint patterns of brain structure and function in
503 inflammatory bowel diseases using multimodal data fusion’, *Neurogastroenterology and Motility*,
504 33(6), pp. 1–10. doi: 10.1111/nmo.14078.

505 Vergun, S. *et al.* (2016) ‘Classification and Extraction of Resting State Networks Using Healthy and
506 Epilepsy fMRI Data.’, *Frontiers in neuroscience*. Switzerland, 10, p. 440. doi:
507 10.3389/fnins.2016.00440.

508 Wang, Y. and Li, T.-Q. (2015) ‘Dimensionality of ICA in resting-state fMRI investigated by feature
509 optimized classification of independent components with SVM.’, *Frontiers in human neuroscience*.
510 Switzerland, 9, p. 259. doi: 10.3389/fnhum.2015.00259.

511 Winkler, A. M. *et al.* (2014) ‘Permutation inference for the general linear model’, *NeuroImage*. The
512 Authors, 92, pp. 381–397. doi: 10.1016/j.neuroimage.2014.01.060.

513 Yeung, A. W. K. (2021) ‘Structural and functional changes in the brain of patients with Crohn’s
514 disease: an activation likelihood estimation meta-analysis’, *Brain Imaging and Behavior*, pp. 1–12.

515 doi: 10.1007/s11682-020-00291-w.

516 Zhang, S. *et al.* (2022) ‘Altered structural covariance and functional connectivity of the insula in
517 patients with Crohn’s disease.’, *Quantitative imaging in medicine and surgery*, 12(2), pp. 1020–1036.
518 doi: 10.21037/qims-21-509.

519 Zigmond, A. S. and Snaith, R. P. (1983) ‘The Hospital Anxiety and Depression Scale. Traduction
520 française : J.F. Lépine.’, *Acta Psychiatrica Scandinavica*, 67(6), pp. 361–370. doi: 10.1111/j.1600-
521 0447.1983.tb09716.x.

522

523 **Figures**

524 Figure 1 Consort diagram outlining the number of CD participants and HCs included in the study

525 Figure 2 Example RSNs and their associated IC number for the template generated from the HC only
526 which were used in the dual regression analysis. Networks shown include visual networks, cerebellar
527 network, frontal parietal network (FPN), default mode network (DMN), salience network (SN),
528 temporal network and dorsal attention network (DAN). Red = positive networks ($2 < z\text{-score} < 5$) and
529 blue = negative networks ($-2 < z\text{-score} < -5$).

530

531 Table 1

	CD (n=25)	HC (n=25)
Age [years]	30 (18-68)	31 (20-65)
BMI [kg/m²]	22 (16-33)	26 (18-30)
Male	16	16
Female	9	9
Ethnicity (% Caucasian)	21	22
TNF α (pg/ml)	0 (0-1233)	9.2 (0-856)
IL-6 (pg/ml)	35.3 (0-259)	12.27 (0-492)
IL1-Beta (pg/ml)	0 (0-1955)	38.5 (0-492)
HADS- Anxiety	5 (1-11)	3.5 (0-15)
HADS - Depression	*3 (0-14)	1(0-8)
Disease duration [years]	7 (1-20)	-
Disease activity defined by Ileocolonoscopy	11	-
Disease activity defined by MRE	12	-
C-reactive protein [mg/dl]	5 (5-224)	-
Faecal calprotectin [μg/g]	458 (18-1800)	-
Harvey Bradshaw index [HBI]	3 (0-9)	-
IBD Fatigue	12 (3-15)	-
Abdominal pain score	10 (0-50)	-
EIM/no EIM	8/17	-

532 **Table 1** Demographic, behavioural, and clinical characteristics of CD participants and HCs. HBI scores (<5 remission, 5-7= mild disease,
533 8-16 = moderate disease, >16 = severe disease. IBD fatigue score= (ranges from 0 to 20, where 0 = no fatigue, 1 to 10 = moderate fatigue,
534 11 to 20 = severe fatigue. HAD score (anxiety and depression) 0 to 7 (normal), 8 to 10 (mild), 11 to 14 (moderate) and 15 to 21 (severe).

535
536

Note: 12 patients had evidence of inflammatory disease at MRE, and 8 patients had evidence of inflammatory disease at colonoscopy, 4 had evidence of inflammatory disease as indicated by FCP levels, 1 patient had evidence of inflammatory disease as indicated by CRP levels and *p<0.005.

RSN	L/R	Voxels	Corrected P-value	MNI (x, y, z)
CD>HC				
<i>Visual Network (IC2&IC3&IC13)</i>				
Inferior temporal gyrus	L	5585	<0.01	-47, -48, -22
Lateral occipital cortex	L	5795	<0.01	-38, -68, 19
Lateral occipital cortex	L	7453	<0.05	-33, -77, 16
OFC	R	5629	<0.05	22, 25, -17
<i>FPN (IC5 &IC11)</i>				
Inferior temporal gyrus	R	5122	<0.05	46, -40, -28
Occipital fusiform gyrus	L	5536	<0.01	-25, -72, -14
Thalamus	R	6299	<0.01	8.6, -6.7, 2.2
Caudate	R	5544	<0.01	8.6, 16, 0.8
PCC	R	6619	<0.01	21, -44, 0.1
Postcentral gyrus	R	6219	<0.01	67, -17, 20
Lingual gyrus	R	5417	<0.01	25, -50, -8
HC>CD				
<i>DMN (IC24)</i>				
Parahippocampal gyrus (PHG)	L	4259	<0.05	-23, -32, -24
Cerebellum	L	6852	<0.05	-18, -50, -30
<i>Salience Network SN (IC8)</i>				
Cerebellum	L	6660	<0.05	-35, -58, -36
Lingual gyrus	R	3094	<0.05	6, -58, -1.6
Postcentral gyrus	R	5960	<0.05	60, -13, 27
<i>Cerebellar Network (IC12)</i>				
Occipital fusiform gyrus	L	4315	<0.05	-32, -73, -19
Cerebellum	L	5990	<0.05	-16, -71, -21

537 **Table 2** Regional alterations in rs-FC between CD participants and HCs using dual regression analysis and a HC network template.

538

RSN	L/R	Voxels	P-value corrected	MNI (x, y, z)
Negative correlation				
<i>Medial Visual Network VI (IC0)</i>				
Precuneus	L	4716	<0.05	-10, -67, 20
<i>Saliency Network SN (IC8)</i>				
Parietal operculum	R	6397	<0.05	37, -33, 18
Positive correlation				
<i>Frontal Network (IC11)</i>				
Cerebellum	R	5760	<0.05*	5, -77, -30

540 **Table 3** RSNs show significant negative and positive correlations with abdominal pain scores in active CD
541 participants, those which are significant after multiple comparisons are shown in *.

542

543

RSN	L/R	Voxels	P-value corrected	MNI (x, y, z)
Positive correlation				
<i>Visual anterior Network (IC2)</i>				
Middle temporal gyrus	R	5798	<0.05*	-62,-29,-17
Planum temporale	R	5816	<0.05	50,-30,14

544 **Table 4** RSNs showing significant positive correlations with disease duration in active CD participants.

545

546

547 **Supplementary Information**

548 Supplementary information is provided in Tables S1 and S2. Table S1 describes the different RSNs and their
549 behavioural interpretation from the literature. Table S2 provides addition information on patient characteristics
550 criteria for diagnosis and medications.

551